This study was designed to examine the role of flavin-containing monooxygenase (FMO) on the auditory and vestibular neurotoxicity of 3,3'-iminodipropionitrile (IDPN) using the FMO substrate and competitive inhibitor methimazole (MMI). Specifically, the purpose was to block the FMO-mediated conversion of IDPN to the putative neurotoxic metabolite N-hydroxy3,3'-iminodipropionitrile (HOIDPN). In three separate experiments, adult male Long-Evans hooded rats were administered (ip) saline (vehicle), MMI, IDPN, or HOIDPN individually, or a combination of IDPN and MMI or HOIDPN and MMI. Animals were observed daily for signs of the ECC syndrome (excitation with choreiform and circling movements) for 10 days. One to 2 weeks after exposure, a battery of behavioral tests was used to examine vestibular and auditory function. MMI completely blocked the neurotoxicity associated with a 600 mg/kg dose of IDPN and partially blocked the effects of a 1000 mg/kg dose of IDPN. In contrast, MMI failed to block, and instead increased, the neurotoxicity associated with HOIDPN. These data suggest that FMOmediated metabolism of IDPN is necessary for the generation of a metabolite responsible for the vestibular and auditory neurotox-
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The synthetic organonitrile 3,3'-iminodipropionitrile (IDPN) is known to produce the ECC syndrome excitation with cho- ' This article has been reviewed by the National Health Effects and Environmental Research Laboratory, U.S. Environmental Protection Agency, and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. This work was supported in part by the North Carolina Agricultural Research Service (M.B.G.), NIEHS Grant ES-00044 (M.B.G.), and NIH Grant NS22688 (L.M.S.). 2 To whom correspondence should be addressed at Neurotoxicology Division [MD-74B] USEPA, R.T.P., NC 27711. E-mail: crofton.kevin® EPAMAIL.EPA.GOV. reiform and circling movements (Delay, 1952; Thullier and Burger, 1954; Selye, 1957) through degeneration of the vestibular system (Slagel and Hartman, 1965; Llorens et al., 1993; Llorens and Dememes, 1994) . IDPN has also been associated with auditory and olfactory damage, and proximal axonopathy (Chou and Hartman, 1964; Griffin et al., 1978; Crofton and Knight, 1991; Genter et al, 1992 Genter et al, , 1994a Crofton et al., 1994) . Currently, the role of metabolism in IDPNinduced neurotoxicity is unclear.
Theories on the activation of LDPN have involved three possible metabolic pathways: (1) cytochrome P450 metabolism, (2) monoamine oxidase (MAO) metabolism, and (3) flavin-containing monooxygenase (FMO) metabolism (e.g., Jacobson et al., 1987) . It has also been suggested that IDPN is the toxic compound and needs no hepatic bioactivation (Llorens and Crofton, 1991) . Tanii et al. (1984) first demonstrated that the neurotoxicity of some related neurotoxic nitriles (e.g., 2-pentenenitrile) was increased by inactivation of hepatic P450s with carbon tetrachloride (CC1 4 ) pretreatment. After observing enhanced vestibular and auditory toxicity of LDPN with CC1 4 pretreatment, Llorens and Crofton (1991) concluded that P450 metabolism is not required to activate IDPN, but instead may define a detoxification pathway. Recent work with deuterated analogs of LDPN suggests that activation of IDPN near the 2-position may be necessary for the behavioral syndrome and peripheral axonopathy (Denlinger et al., 1992 (Denlinger et al., , 1994 . Genter et al. (1994a) conducted a series of studies in which olfactory P450 isoform 2E1 concentrations were manipulated. They concluded that olfactory mucosal P4502E1 activation of IDPN was necessary for olfactory epithelial degeneration. Wilmarth and Froines (1991) used pargyline to inhibit MAO metabolism and found no change in the toxicity of IDPN, suggesting that this pathway is involved in neither the bioactivation nor detoxification of LDPN. The urinary metabolites of IDPN, /5-aminopropionitrile (BAPN), cyanoacetic acid, and /9-alanine (Markow et al., 1959; Williams et al., 1970) , have also been tested for neurotoxicity. None of these metabolites are neurotoxic, and they are therefore assumed to be detoxification products. Morandi et al. (1987) first postulated that FMO was the enzyme system responsible for IDPN activation. Based upon the chemical reactivity and structure of IDPN, FMO metabolism was hypothesized to convert IDPN to N-hydroxy-IDPN (HOIDPN). Rats exposed to HOIDPN exhibit the same signs of neurotoxicity as IDPN (Morandi et al., 1987; Engelhart, 1994; Crofton et al., 1996) , but the effects are reported to be two to eight times greater than that of the parent compound. Recently, Engelhart (1994) documented the in vitro conversion of IDPN to HOIDPN via FMO metabolism in rat liver microsomes, as well as in vivo inhibition of the IDPN syndrome and proximal axonopathy by methimazole (MMI) in the rat. These data suggest that HOIDPN is either the ultimate toxicant or an intermediate in the pathway to the ultimate toxicant.
To increase our understanding of the role of metabolic activation of IDPN and extend the previous findings of Engelhart (1994) , we examined the effects of competitive inhibition of FMO on IDPN-induced neurotoxicity. The present study had two specific aims. The first was to evaluate the auditory and vestibular effects of IDPN following inhibition of FMO. Since no effective reversible or irreversible inhibitor of FMO has yet been identified, competitive inhibition was achieved by use of the alternate substrate MMI (Poulsen et al., 1979; Kedderis and Rickert, 1985; Ziegler, 1993) . MMI-induced competitive inhibition of FMO was hypothesized to block the conversion of IDPN to HOIDPN, thus preventing the vestibular and auditory toxicity. The second aim of the present study was to determine whether HOIDPN itself or a subsequent metabolite is the ultimate toxicant generated from EDPN. Since N-hydroxylated metabolites of secondary amines are often better substrates for FMO metabolism (to the corresponding nitrone) than are the corresponding secondary amines (Ziegler, 1988) , FMO might bioactivate not only IDPN, but also HOIDPN (see Morandi et al., 1987; Engelhart, 1994) .
To examine these aims, rats were exposed to saline, MMI, IDPN, or HOIDPN alone or a combination of IDPN plus MMI or HOIDPN plus MMI. End points were chosen for evaluation of alterations in vestibular and auditory function. Behavioral observations and motor activity have been shown to be good indicators of the vestibular effects of IDPN (Llorens and Crofton, 1991; Llorens et al., 1993) . IDPN exposure also results in hearing loss which is associated with the destruction of hair cells in the auditory system . No characterization of the effects of MMI on the olfactory toxicity of IDPN or HOIDPN was attempted due to the direct toxicity of MMI to the nasal mucosa (Brittebo, 1995; Genter et al., 1994b Genter et al., , 1995 .
METHODS AND MATERIALS

Animals.
Male Long-Evans hooded rats (Charles River, Inc., Raleigh, NC) were obtained at approximately 60 days of age and were housed two per cage in standard polycarbonate hanging cages (24 x 24 x 45 cm) with heat-treated pine chip bedding (Northeastern Products, Warrensburg, NY). All animals were given an acclimation period of 5 to 30 days and were maintained on a 12:12 hr light:dark photoperiod (0600:1800). Food (Purina Lab Chow, Barnes Supply, Durham, NC) and tap water were provided ad libitum. Room temperature was maintained at 21.0 ± 2°C and relative humidity at 40 ± 209b. All experiments were approved in advance by the Animal Care Committee of the National Health and Environmental Effects Research Laboratory (NHEERL) and were conducted in accordance with the Society of Toxicology (SOT) guidelines.
Exposure and general observations. Animals were exposed to saline (vehicle), MMI, IDPN, or HOIDPN alone or a combination of IDPN or HOIDPN plus MMI. Table 1 illustrates the dosing scenarios used in the three experiments. IDPN and MMI doses and durations were chosen from previous work (Crofton and Knight, 1991; Llorens et al, 1993; Genter et al, 1995) . The HOIDPN dose was based on pilot experiments {n = 2J group) in which 250 mg/kg (intraperitoneally, ip) was the lowest dose that would induce the ECC syndrome. MMI (98% pure, Sigma, St. Louis, MO) was administered ip in dimethyl sulfoxide (DMSO) at 300 mg/kg/day (0.5 ml/kg) for two (MMIJ or four doses (MML,). Single doses of IDPN (99%, Kodak, Rochester, NY) were administered ip in saline at 600 mg/kg (1.0 ml/kg; IDPNJ or 1000 mg/kg (2.0 ml/kg; IDPN H ). Single doses of HOIDPN were administered ip in saline at 250 mg/kg (1.0 ml/kg). HOIDPN was synthesized by treatment of a methanolic solution of hydroxylarrune with excess acrylonitrile as reported in Morandi et al (1987) . All animals were observed for any clinical signs associated with the ECC syndrome during daily weighings (Days 1 -10, 18, and 25).
Vestibular toxicity. Animals were rated for signs of vestibular toxicity 8 days following exposure using a modification of previously published procedures (Diamond et al, 1982; Crofton et al, 1996) . Animals were placed on a table top and scored for the presence or absence of the following signs: circling, retropulsion, dyskinetic head movements, tail hang test, forelimb placement test, and inverted screen test. Observations lasted 2 min per animal. Animals were given a rating for each activity (0, normal behavior, 1, abnormal behavior associated with ECC syndrome). After completion of all other testing, animals were rated in a swim test. The animals were placed in a round plastic container (56 cm diameter x 75 cm height) filled with tap water (40 cm) and rated for swimming ability. Ratings were 0, good swimmer; 1, troubled swimming; and 2, unable to swim. The scores of all observational testing were summed per animal. The maximum score of eight was indicative of all signs of the ECC syndrome.
Motor activity was measured using the procedure of Reiter et al. (1975) as modified by Crofton et al. (1996) . Testing was conducted for 1 hr in 16 figure-eight mazes, each consisting of a series of interconnected alleys (10 x 10 cm) converging on a central arena and covered with transparent acrylic plastic. Horizontal motor activity was detected by eight phototransistor/ photodiode pairs located 2.5-3.0 cm from the floor of each maze. Vertical activity was recorded by four additional photobeams located 12.5 cm above the floor in the central area (Crofton et al, 1996) . Each time a photobeam was interrupted, one activity count was registered. Animals were tested individually.
Auditory toxicity. Testing was conducted in eight sound-attenuated chambers, each containing a wire mesh plastic-framed test cage mounted on a load cell/force transducer assembly designed to measure vertical force (see Ruppert et al, 1984, for details) . Auditory thresholds and the acoustic startle reflex (ASR) amplitude were tested using the reflex modification audiometry procedure of Young and Fetcher (1983) (for review see Crofton et aL, 1990; Crofton, 1992) . Each rat was placed in a test cage located in a sound-isolating chamber and, following a 10-min adaptation period at an ambient noise level of 30 dB (Aweighted), received a total of 240 trials. There were 10 trials at each of 23 levels of the prepulse stimulus [S1, 40-msec, -6 to 90 dB SPL (sound pressure level), Note. The abbreviations (used in the paper) identifying the dose groups are in the first column and the corresponding dose is listed to the right.° MMI was administered in DMSO 30 min prior to nitrile administration and daily afterward according to the times shown.
in 3-or 6-dB increments]. The eliciting stimulus (S2) was a 120-dB, 40-msec burst of white noise (generated by a 32-stage linear feedback shift register). Each rat also received 10 blank control trials, during which only S2 was presented.
The order of presentation of the trials was computer-generated in a semirandom, but balanced fashion, so that within each of 10 24-trial blocks, each S1/S2 condition was presented once. The intertrial interval was 15 sec, and the interstimulus interval (measured from onset of S1 to onset of S2) was 90 msec. Each block of animals was tested over a 2-day period, one frequency per day (1 and 40 kHz). The reflex modification threshold (RMA) (i.e., auditory threshold) was determined using a nonlinear regression procedure (SAS, 1989) . RMA thresholds were defined as the SI intensity above which the response to S2 was inhibited (see Crofton el aL, 1990; Crofton, 1992 , for details).
Statistics. Analysis of variance (ANOVA) procedures were used for all main and simple-effects tests (SAS, 1989) . In the case of more than one independent variable, significant interactions were followed by simpleeffects ANOVA tests for each independent variable. Main effects and interactions were analyzed using a three-way ANOVA. Repeated-measures ANOVAs (multivariate) were used where appropriate. Mean contrast comparisons between each dosage group and the vehicle control were made using Tukey's studentized range test. An alpha level of 0.05 was used for all step-down (simple-effects) and mean contrast tests. Body weight data were analyzed and graphed as percentage of pretreatment weights to compensate for small pretreatment differences in group means. There were no significant interactions between frequency (1 and 40 kHz) and treatment in any of the experiments (p > 0.05). Therefore, in order to simplify graphics and save space, data for the two frequencies were averaged for each animal for the ASR amplitude and threshold measurements.
RESULTS
Body Weight
Experiment 1. MMI treatment moderated the body weight loss associated with IDPN exposure with maximal effect on Day 9 (Day 9 data shown in Fig. 1 A) . All treatment groups displayed decreased body weights from Day 3 through Day 5 (p < 0.05; data not shown). This effect continued in the LDPN H and LDPN H + MMI2 groups through Day 8 with body weight losses of 12-20% (p < 0.05). The greatest difference in body weight loss was on Day 9, with a partial block of body weight loss by MMI in the LDPN H + MMI2 group (Fig. 1A ). There was a significantly smaller body weight loss in the LDPN H + MMI 2 group compared to the IDPN-alone group (p < 0.05). The IDPN H group did not reattain preexposure body weights, while animals receiving LDPNH + MMI 2 returned to preexposure weights by the end of the experiment. There was a time X treatment interaction (F(27,47) = 4.65, p < 0.0001) and main effects of treatment were observed from Day 2 through the end of the experiment (all Fs(3,28) > 16.44, p < 0.0001).
Experiment 2. All treatments caused decreased body weights, and MMI moderated the body weight losses induced by both doses of LDPN (maximal effects on Day 9 shown in Fig. IB) . MML, caused significantly decreased body weights from Day 3 through Day 10 (data shown for Day 9). Observations after injections of MMI showed the rats to be nonactive and lethargic. This may have reduced the amount of food intake and resulted in a temporary loss of body weight which reversed over time. MMI partially blocked the body weight loss in both LDPN groups. The LDPN L + MMI 2 group had significantly less weight loss compared to the IDPN L group on Days 2-6, 18, and 25 (p < 0.05). The LDPN H + MML, group had significantly less weight loss compared to the LDPN H group on Days 8-25 (p < 0.05). All groups were similar to the control group by the end of the study, except for the two groups receiving IDPN alone, which were at or below preexposure weights. These conclusions were supported by a time X treatment interaction (F(50,l 13) = 5.60, p < 0.0001) and by main effects of treatment on all days (all Fs(5,42) > 14.56, p < 0.0001).
Experiment 3. MMI did not block the weight loss associated with HOIDPN (maximal effects on Day 6 shown in Fig. 1C ). Body weight loss was similar for all treatment groups. All treated animals lost body weight (10 to 15%) over the first 6 days {p < 0.05, data not shown). Thereafter, these animals recovered to a rate of weight gain similar to controls, but never reached control body weights. There was a time X treatment interaction (F(32,83) = 7.23, p < 0.0001). There were main effects of treatment from Day 2 through the end of the experiment (all Fs(4,34) > 17.27, p < 0.0001).
Vestibular Toxicity
Experiment 1. MMI treatment just prior to and 24 hr after a 1000 mg/kg dose of IDPN delayed the onset and partially blocked the severity of the ECC syndrome (Fig. 2 , Table 2 ). Animals in the IDPN H group were all symptomatic by Day 4, while animals receiving IDPN H + MMI 2 did not display any signs of the ECC syndrome until Day 7. Six of eight animals in the IDPN H + MMI 2 group showed only mild signs (e.g., head bobbing only) of the ECC syndrome (Fig. 2) . The reduction in severity of the ECC syndrome in the IDPN H + MMI 2 group is illustrated by the observational scores on Day 8 (Table 2, Fig. 2 ). There was a 70% decrease in the severity score in the IDPN H + MMI 2 group compared to the IDPN H group. No adverse clinical signs were observed in the control or MMI 2 groups.
MMI treatment completely blocked the IDPN-induced changes in motor activity (Fig. 5A) . The IDPN H group had significantly increased horizontal and decreased vertical activity. In contrast, the IDPN H + MMI 2 group was not significantly different from the control or MMI 2 -alone groups for both types of activity (p < 0.05). This was supported by main effects of treatment for horizontal (F(3,28) = 11.33, p < 0.0001) and vertical activity (F(3,28) = 18.79, p < 0.0001).
Experiment 2. The ECC syndrome associated with a 600 mg/kg dose of IDPN was completely blocked with two doses of MMI (Fig. 3, Table 2 ). Four daily doses of MMI delayed the onset and decreased the severity of a 1000 mg/kg dose of IDPN (Fig. 3, Table 2 ). The 3-day lag between the IDPN H + MMI4 and IDPN H groups seen in Experiment 1 was also observed here. The two additional doses of MMI (four total) reduced the severity of the ECC syndrome in the IDPN from 23 to 5% (Table 2) . No adverse clinical signs were observed in the control or MMI groups.
MMI treatment completely blocked the motor activity effects of both doses of IDPN (Fig. 5B ). Horizontal and vertical activities were increased and decreased, respectively, in the IDPN L and IDPN H groups (p < 0.05), whereas there were no significant differences between the control group and the IDPN L + MMI 2 and IDPN H + MML, groups (p > The time course of onset of the behavioral syndrome. MMI treatment completely blocked the onset in the 600 mg/kg IDPN group and caused a 3-day lag in the onset in die 1000 mg/kg IDPN group. [Note that symbols are offset slightly on the x-axis for graphical purposes. Data are presented as the percentages of animals in each group displaying any signs of the ECC syndrome.] (Right) Severity scores. MMI treatment completely blocked the toxicity associated with a 600 mg/kg dose of IDPN and resulted in a 95% decrease in die severity score associated with a 1000 mg/kg dose of IDPN. [Notes: Data are presented as group means (±SE); nd, not detected; *, significantly different from the saline control; **, also significantly different from the respective IDPN/MMI group, p < 0.05, Tukey's.] 0.05). There were main effects of treatment for both horizontal (F(5,40) = 5.40, p < 0.0007) and vertical activity (F(5,40) = 18.88, p < 0.0001).
Experiment 3. The onset and severity of the ECC syndrome was enhanced in the groups receiving both HOIDPN and MMI (Fig. 4, Table 2 ). Animals receiving HOIDPN with either two or four doses of MMI displayed ECC signs within 4 days. In contrast, signs of the ECC syndrome were not apparent until Day 6 in the HOIDPN-alone group. Data from Day 8 demonstrate that the severity of the ECC syndrome was significantly increased in the HOIDPN + MMI 2 and HOIDPN + MML, groups when compared to HOIDPN alone (Table 2) . No adverse clinical signs were observed in the control or MMI groups.
Similar to the behavioral signs, both MMI treatments exacerbated the effects of HOIDPN on motor activity (Fig. 5C) . HOIDPN alone at the 250 mg/kg dose did not significantly increase horizontal activity, nor did it decrease vertical activity (p > 0.05). However, horizontal activity was significantly increased and vertical activity was significantly decreased in the 
Auditory Toxicity
Experiment I. The ototoxicity of IDPN was clearly blocked in animals concurrently exposed to both IDPN and MMI (Fig. 6A) . FDPNH animals had a complete loss of hearing (up to the highest intensity tested, 90 dB) and severely depressed ASR amplitudes (amplitude data not shown), whereas the ASR amplitudes in the MMI 2 -alone and IDPN H + MMI 2 groups were not statistically different from the controls {p > 0.05). Supporting these conclusions were main effects of treatment for ASR amplitudes (F(3,28) = 9.79, p < 0.0001) and average thresholds (F(3,28) = 85.65, p < 0.001).
Experiment 2. MMI completely blocked the ototoxic effects of both the 600 and 1000 mg/kg doses of IDPN (Fig.   6B ). The EDPN L and IDPN H doses caused a severe depression in ASR amplitudes and a significant hearing loss (p < 0.05). The ASR amplitudes and thresholds for the MML,, IDPN L + MMI 2 , and IDPN H + MMLt groups were not significantly different from the control group (p > 0.05). Supporting this conclusion were main effects of treatment for both ASR amplitude (F(5,40) = 9.57, p < 0.0001) and average thresholds (F(5,40) = 54.96, p < 0.0001).
Experiment 3. MMI treatment significantly increased the ototoxicity of HOIDPN (Fig. 6C) . The HOIDPN-alone group had a moderate increase in the average threshold (~16 dB relative to the control group, p < 0.05), whereas the HOIDPN + MM1 2 and HOIDPN + MMI4 groups displayed large increases in averaged thresholds (~55 dB relative to controls, p < 0.05). The HOIDPN + MMI 2 and HOIDPN + MML, groups were also significantly increased relative to the HOIDPN-alone group (p < 0.05). Treatment-related differences in the ASR amplitudes were similar to the threshold effects, except that 138 NACE ET AL. there was no significant increase in the HOIDPN-alone group relative to the control group (p > 0.05). These conclusions were supported by main effects of treatment for both ASR amplitudes (F(4,34) = 6.89, p < 0.0004) and averaged thresholds (F(4,33) = 42.1, p < 0.0001).
DISCUSSION
The present findings clearly demonstrate that the vestibular and auditory toxicities induced by acute exposure to IDPN can be blocked by concurrent administration of MMI. This finding is consistent with Engelhart (1994) who blocked the ECC syndrome and axonal swellings induced by IDPN with coadministration of MMI. Furthermore, the present data show that MMI fails to block the HOFDPN-induced auditory and vestibular effects. In fact, coadministration of MMI and HOIDPN actually exacerbates this neurotoxicity of HOIDPN. These data suggest that FMO-mediated metabolism is required for bioactivation of IDPN to HOIDPN and that further FMO-mediated metabolism of HOIDPN is a detoxification pathway for HOIDPN.
The data presented here extend previous findings (Engelhart, 1994) and clearly demonstrate that competitive inhibition of FMO with MMI blocks the otovestibular neurotoxicity of IDPN, consistent with the hypothesis that conversion of IDPN to HOIDPN is a toxic activation step (Morandi et al., 1987; Engelhart, 1994) . The antagonistic effects of MMI on all the neurotoxic end points were dependent on the dose of IDPN. MMI completely blocked the toxicity of IDPN at 600 mg/kg and partially blocked the toxicity at 1000 mg/ kg. The pre-and posttreatment of animals with MMI altered the quantitative effects of IDPN, but not the qualitative effects. The neurotoxic effects of IDPN reported here are similar (i.e., signs of vestibular dysfunction and hearing loss) to those previously seen with acute and short-term exposures (Crofton and Knight, 1991; Llorens and Crofton, 1991; Llorens et al., 1993) . Furthermore, the degree of antagonism was also dependent upon the duration of MMI administration. Four daily doses of MMI were more effective than two daily doses in reducing the severity of a 1000 mg/kg dose of IDPN. MMI also partially blocked the body weight loss normally observed after acute exposures to IDPN (Peele et al, 1990; Crofton and Knight, 1991; Crofton et al, 1996) . The reason for small decreases in body weight in the MMI4 group is currently unknown.
The present findings coupled with those previously reported (Engelhart, 1994 ) strongly suggest that FMO-mediated metabolism of IDPN to HOIDPN is a critical event in the production of the neuroactive species. These findings may not appear to be entirely consistent with previous views on the role of metabolism in the neurotoxicity of IDPN. Llorens and Crofton (1991) observed an increase in toxicity after decreasing P450 activity with systemic CCU treatment and concluded that hepatic bioactivation of IDPN was not necessary to induce neurotoxicity. However, this increase in toxicity could be explained by assuming that CCI4 compromised P450 activity, thereby removing an IDPN detoxification pathway, resulting in increased levels of IDPN for conversion to HOIDPN and thus the observed increase in neurotoxicity.
Evidence that liver P450 metabolism serves as a detoxification pathway is that metyrapone, which was shown in vitro to potently inhibit liver microsomal P450 oxidative N-dealkylation of IDPN (giving /3-aminopropionitrile), had no significant effect on the in vivo morphological or vestibular neurotoxicity of IDPN (Engelhart, 1994) . In addition, Denlinger et al. (1992) reported that deuteration at the 3-position of IDPN increased neurotoxicity. These authors suggested that metabolism at this position, which would be slowed by a primary kinetic isotope effect, represents detoxification. Although these workers did not recognize it, their data also support a detoxifying role for the P450-mediated oxidative N-dealkylation of IDPN, which involves rate-limiting C-H bond breaking at C-3. The fact that the P450 reaction produces both /6-aminopropionitrile and cyanoacetaldehyde, the latter being further oxidized to cyanoacetic acid (see Jacobson et al., 1987) , explains the later finding by Denlinger et al. (1994) that deuteration at the 3-position of IDPN also results in reduced urinary output of cyanoacetic acid.
The evidence that P450 metabolism of EDPN is a detoxification pathway insofar as the morphological and vestibular neurotoxicity is concerned, however, appears to conflict with the conclusion of Genter et al. (1994) regarding the olfactory toxicity of IDPN. The latter was proposed to arise from a P450 2E1-mediated bioactivation pathway within the olfactory mucosa. Genter et al. (1994) demonstrated that induction of P450 2E1 was associated with an increase in the olfactory toxicity of IDPN and that inhibition of P450 activities with either metyrapone or CC1 4 eliminated or significantly reduced the olfactory toxicity of IDPN. This brings into question whether the MMI antagonism of the otovestibular toxicity of IDPN might arise from inhibition of a P450 bioactivation pathway, since in addition to competitive inhibition of FMO, MMI also decreases P450 activity (Lee and Neal, 1978; Kedderis and Rickert, 1985) . If this were the case, one could propose a common toxic activation mechanism, i.e., P450-based activation, for both the otovestibular and olfactory neurotoxic components of IDPN. However, a P450-based activation of IDPN in relation to the otovestibular and axonopathic effect appears untenable for a number of reasons. First, inactivation of P450 by MMI metabolites is only partial, with a decrease in the range of 25% (Kedderis and Rickert, 1985) . Second, metyrapone, which potently inhibits P450s in vitro, failed to block the vestibular and peripheral neurotoxicity of IDPN in vivo, whereas MMI decreased the severity of both the ECC syndrome and the axonopathy in vivo (Engelhart, 1994) . This discrepancy between the mechanism for the otovestibular and olfactory toxicilies of IDPN leads to the suggestion that there may be a divergence in the bioactivation of IDPN between the pathway responsible for the olfactory toxicity (i.e., P450-mediated) and that responsible for the otovestibular toxicity (i.e., FMO-mediated) .
The present study demonstrated that when MMI-treated rats did develop signs of the ECC syndrome, the onset was delayed compared to the development of symptoms with IDPN alone. There was a 4-day lag period for the manifestation of the ECC syndrome in the high dose of IDPN + MMI animals compared to the animals receiving IDPN alone (Figs. 2 and 3) . This suggests that IDPN may have a longer half-life than MMI. Data to support this hypothesis have not been reported.
This study also showed that cotreatment with the FMO substrate MMI enhanced the neurotoxic effects of an acute dose of HOIDPN. HOIDPN itself produced effects on behavior similar to those reported in previous studies (Morandi et al., 1987; Engelhart, 1994; Crofton et al., 1996) . MMI treatment increased the severity of both the vestibular and auditory end points. The severity scores for the ECC syndrome were increased by approximately 50% with MMI treatment, and the onset time was shortened by about 2-3 days. MMI treatment increased the magnitude of the HOIDPN effects on motor activity at a HOIDPN dose which by itself had little effect (Fig. 5C ). Significant HOIDPNinduced motor activity deficits previously reported (Crofton et al., 1996) are likely due to the fact that this study used three daily doses of 100 mg/kg, whereas the present work used only a single 250 mg/kg dose. Finally, MMI treatment caused a dramatic increase in hearing loss compared to the HOIDPN-alone group. Clearly, MMI treatment enhanced the neurotoxicity of HOIDPN.
The finding that MMI did not diminish the otovestibular toxicity of administered HOIDPN suggests that FMO activation beyond HOIDPN is not required. In fact, the unexpected result that MMI instead increased these neurotoxic effects of HOIDPN, described here for the first time, indicates that HOIDPN either is the active metabolite or is further activated by a non-FMO pathway and that FMO metabolism of HOIDPN is a detoxification pathway. Finally, although we cannot exclude the possibility of further enzymatic and/or spontaneous activation of HOIDPN, we find no support for the proposal by Denlinger et al. (1994) that the reactive IDPN species is derived from the activation of the bifunctional nitrile groups of the intact molecule.
In summary, these experiments demonstrate that the neurotoxicity of IDPN is blocked by administration of the FMO inhibitor MMI. These data suggest that IDPN must be bioactivated via FMO, possibly to HOIDPN, in order to induce the vestibular and auditory toxicities. Furthermore, MMI treatment failed to block, but instead exacerbated, the neurotoxicity of HOIDPN. This suggests that HOIDPN, or a non-FMO-mediated metabolite of HOIDPN, may be the ultimate bioactive species.
